Abbott
(NYSE: ABT)
and Tandem Diabetes Care (Nasdaq:TNDM) today announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump.
This marks the first automated insulin delivery system to integrate the newly available Abbott FreeStyle Libre 2 Plus sensor. The FDA cleared the updated Abbott continuous glucose monitor (CGM) for use with automated insulin delivery in March 2023. For the first time, users of the leading CGM sensor can utilize a hybrid closed-loop system to manage their diabetes.
Integration of these technologies comes shortly after Tandem became the first to integrate with the next-generation Dexcom G7 CGM. The t:slim X2 insulin pump with Control-IQ technology previously worked with the Dexcom G6.
Get the full story at our sister site, Drug Delivery Business News.